{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:59Z","timestamp":1772166599738,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Of patients receiving moderate emetic risk chemotherapy (MEC), 30\u201390% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, prospective, observational study of adults treated with MEC while receiving chemotherapy for various cancer types in Japan, the enrolled patients kept diaries documenting CINV. All participants received a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 400 patients enrolled from May 2013 to January 2015, 386 were eligible for evaluation. The median age was 64 (range, 26\u201384). The overall complete response (CR; no emetic events and no antiemetic measures) rate was 64%. The proportion of patients showing CR was low in the carboplatin (CBDCA)- and oxaliplatin-based chemotherapy groups, especially among women. We showed that the CR rates in men were high in the CBDCA (AUC5)\u2009+\u2009etoposide (ETP) (80%), capecitabine plus oxaliplatin (CAPOX) (78%), and CBDCA+ paclitaxel (PTX) groups for lung cancer (73%). Total control (TC; no emetic events, no antiemetic measures, and no nausea) and complete control (CC; no emetic events, no antiemetic measures, and less than mild nausea) were achieved in 51 and 61% of patients, respectively. Logistic regression analysis revealed history of motion sickness, history of pregnancy-associated vomiting and CBDCA-based chemotherapy as risk factors for CR and history of motion sickness and history of pregnancy-associated vomiting as risk factors for TC. Additional, Ages \u226565\u2009years is an independent predictive factor for achieving TC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data showed that two antiemetics were insufficient to control CINV in patients receiving CBDCA- or oxaliplatin-based chemotherapy. However, two antiemetics may be sufficiently effective for elderly male patients receiving CBDCA (AUC5)\u2009+\u2009ETP, CBDCA+PTX for lung cancer, or CAPOX. Additionally, we consider that three antiemetics are necessary for women with colorectal cancer receiving CAPOX. Risk factor analysis related to CR showed that CINV prophylaxis in patients treated with CBDCA-based chemotherapy was generally supportive of the guideline-recommended three antiemetics. However, the control of nausea in patients receiving non-CBDCA-based chemotherapy is a key point to note. The further individualization of antiemetic regimens for patients receiving MEC based on both types of chemotherapy regimens and sex is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-020-00445-y","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:02:54Z","timestamp":1601996574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Reiko","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"445_CR1","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240\u201361.","journal-title":"J Clin Oncol"},{"key":"445_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mdw345.10","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al. MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:110\u201333.","journal-title":"Ann Oncol"},{"key":"445_CR3","unstructured":"NCCN Guidelines Insights: Antiemesis, Version2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 23 Apr 2020."},{"key":"445_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","volume":"722","author":"D Warr","year":"2014","unstructured":"Warr D. Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol. 2014;722:192\u20136.","journal-title":"Eur J Pharmacol"},{"key":"445_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104:711\u20137.","journal-title":"Cancer Sci"},{"key":"445_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2017","unstructured":"Takemoto H, Nishimura J, Komori T, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2017;22:88\u201395.","journal-title":"Int J Clin Oncol"},{"key":"445_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27:1601\u20136.","journal-title":"Ann Oncol"},{"key":"445_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","volume":"18","author":"Y Tsuji","year":"2017","unstructured":"Tsuji Y, Baba H, Takeda K, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18:753\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"445_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Masato Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell lung cancerreceiving carboplatin-based chemotherapy. Lung Cancer. 2014;84:259\u201364.","journal-title":"Lung Cancer"},{"key":"445_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study Group of Japan. Int J Clin Oncol. 2015;20:855\u201365.","journal-title":"Int J Clin Oncol"},{"key":"445_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18:423\u201331.","journal-title":"Support Care Cancer"},{"key":"445_CR12","first-page":"871","volume":"51","author":"J Kaushal","year":"2010","unstructured":"Kaushal J, Gupta MC, Kaushal V, et al. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J. 2010;51:871\u20135.","journal-title":"Singapore Med J"},{"key":"445_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015;51:1274\u201382.","journal-title":"Eur J Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-020-00445-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T03:42:24Z","timestamp":1633491744000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00445-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00445-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16203\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16203\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16203\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16203\/v5","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16203\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"15 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures in studies involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the National Cancer Center Institutional Review Board (2012\u2013324) and the Institutional Review Board of each participating hospital. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Koichi Goto has received a speaker honorarium fee from AstraZeneca, Bristol-Myers Squibb, ONO, Chugai, Eli Lilly, MSD, and Pfizer and research grants from Dainippon Sumitomo Pharma, MSD, Astellas, AstraZeneca, ONO, Kyowa Hakko Kirin, Daiichi Sankyo, TAIHO, Takeda, Chugai, Eli Lilly, Novartis, Nippon Boehringer lngelheim, Pfizer, Merck Serono, Bristol-Myers Squibb, Janssen Pharmaceutical, Ignyta, Loxo Oncology, Sysmex, Life Technologies Japan, RIKEN GENESIS, Oxonc. Takashi Seto has received a speaker honorarium fee from Astra Zeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MDS, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, and Takeda Pharmaceutical and research grants from Astellas Pharma, Astra Zeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, LOXO Oncology, Merck Serono, MDS, Nippon Behringer Ingelhim, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical. Masato Nishio has received a speaker honorarium fee from ONO, Bristol Myers Squibb, Pfizer, Chugai, Eli Lilly, TAIHO, AstraZeneca, Boehringer-ingelheim, MDS, Novartis, Daiichi Sankyo Healthcare, and Merck Sereno and research grants from MSD, Novartis, OnO, Chugai, Bristol Myers Squibb, TAIHO, Eli Lilly, AstraZeneca, Pfizer, and Astellas. Naoyuki Nogami has received a speaker honorarium fee from Pfizer, Chugai, Eli Lilly, TAIHO, Astra Zeneca, Kyowa Hakko Kirin, MDS, ONO. Hirotsugu Kenmotsu has received a speaker honorarium fee from ONO and AstraZeneca and research grants from Astra Zeneca, Boehringer Ingelheim, Chugai, and Daiichi Sankyo. Hiroyasu Kaneda has received a speaker honorarium fee from ONO Pharmaceutical Industries, Pfizer, Chugai, Eli Lilly, TAIHO, Astra Zeneca, and MDS.We have received financial support for the design of the study and collection, analysis and interpretation of the data in this study from Public Health Research Foundation (PHRF).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}